The Long-Term Analysis of Hematological Malignancies: Patients with COVID-19 versus without COVID-19

IF 0.3 Q3 MEDICINE, GENERAL & INTERNAL

Klimik Journal Pub Date : 2022-08-22 DOI:10.36519/kd.2022.4182

A. Tekinalp, T. U. Kars, H. Z. Dikici, Sinan Demircioğlu, Özcan Çeneli

{"title":"The Long-Term Analysis of Hematological Malignancies: Patients with COVID-19 versus without COVID-19","authors":"A. Tekinalp, T. U. Kars, H. Z. Dikici, Sinan Demircioğlu, Özcan Çeneli","doi":"10.36519/kd.2022.4182","DOIUrl":null,"url":null,"abstract":"Objective: The study aims to determine the frequency and clinical features of COVID-19 during the long-term follow-up of patients with hematological malignancies.\n\nMethods: Patients with hematological malignancies followed in our center were evaluated retrospectively. The patients were divided into two groups with having COVID-19 between April 01, 2020, and July 01, 2021: those who had COVID-19 [COVID (+)] and those who didn’t have COVID-19 [COVID (-)].\n\nResults: 1258 patients were evaluated. Of these, 288 (22.9%) were found to have had COVID-19. The most common and least common diagnoses in the COVID (+) group were non-Hodgkin lymphoma (NHL) (21.7%) and Hodgkin lymphoma (HL) (6.9%), respectively. The malignancies with the highest and lowest rates of COVID-19 (+) were multiple myeloma (MM) (35.6%) and chronic myeloid leukemia (CML) patients (17.8%), respectively. The median age was higher in COVID (+) chronic lymphocytic leukemia (CLL) patients than in COVID (-) patients (73 vs. 66; p= 0.001). All deaths were due to COVID in COVID (+) patients. The mortality rate for all patients was found to be significantly higher in the COVID (+) group than in the COVID (-) group (22.8% vs. 11.9%; p<0.001). Myelodysplastic syndrome (MDS) (39.5%) and acute leukemia (AL) (35.7%) had the highest mortality rates in the COVID (+) group. The mortality rates in COVID (+) CLL (26% vs. 7%), AL (35.7% vs. 17.7%) and MM (28.6% vs. 9.2%) were significantly higher than in the COVID (-) group. There were no deaths due to COVID-19 in CML patients. 79.8% of COVID (+) patients were hospitalized, and the mortality rate in these patients was significantly higher than in outpatients (34.6% vs. 2.8%; p<0.001). The patients with the highest need for mechanic ventilation had MDS (44.8%) and AL (36%).\n\nConclusion: Our study provides important data to the literature comparing the effect of SARS-CoV-2 on all hematological malignancies with malignant patients who do not have COVID-19.\n\nKEYWORDS\nCOVID-19, hematological malignancies, pandemic, SARS-CoV-2","PeriodicalId":44309,"journal":{"name":"Klimik Journal","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2022-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klimik Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36519/kd.2022.4182","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The study aims to determine the frequency and clinical features of COVID-19 during the long-term follow-up of patients with hematological malignancies. Methods: Patients with hematological malignancies followed in our center were evaluated retrospectively. The patients were divided into two groups with having COVID-19 between April 01, 2020, and July 01, 2021: those who had COVID-19 [COVID (+)] and those who didn’t have COVID-19 [COVID (-)]. Results: 1258 patients were evaluated. Of these, 288 (22.9%) were found to have had COVID-19. The most common and least common diagnoses in the COVID (+) group were non-Hodgkin lymphoma (NHL) (21.7%) and Hodgkin lymphoma (HL) (6.9%), respectively. The malignancies with the highest and lowest rates of COVID-19 (+) were multiple myeloma (MM) (35.6%) and chronic myeloid leukemia (CML) patients (17.8%), respectively. The median age was higher in COVID (+) chronic lymphocytic leukemia (CLL) patients than in COVID (-) patients (73 vs. 66; p= 0.001). All deaths were due to COVID in COVID (+) patients. The mortality rate for all patients was found to be significantly higher in the COVID (+) group than in the COVID (-) group (22.8% vs. 11.9%; p<0.001). Myelodysplastic syndrome (MDS) (39.5%) and acute leukemia (AL) (35.7%) had the highest mortality rates in the COVID (+) group. The mortality rates in COVID (+) CLL (26% vs. 7%), AL (35.7% vs. 17.7%) and MM (28.6% vs. 9.2%) were significantly higher than in the COVID (-) group. There were no deaths due to COVID-19 in CML patients. 79.8% of COVID (+) patients were hospitalized, and the mortality rate in these patients was significantly higher than in outpatients (34.6% vs. 2.8%; p<0.001). The patients with the highest need for mechanic ventilation had MDS (44.8%) and AL (36%). Conclusion: Our study provides important data to the literature comparing the effect of SARS-CoV-2 on all hematological malignancies with malignant patients who do not have COVID-19. KEYWORDS COVID-19, hematological malignancies, pandemic, SARS-CoV-2

查看原文本刊更多论文

血液系统恶性肿瘤的长期分析:COVID-19患者与非COVID-19患者

目的：本研究旨在确定新冠肺炎在血液系统恶性肿瘤患者长期随访中的发病率和临床特征。方法：对我中心随访的血液系统恶性肿瘤患者进行回顾性评价。将2020年4月1日至2021年7月1日期间患有新冠肺炎的患者分为两组：患有新冠肺炎的患者[新冠肺炎（+）]和未患有新冠肺炎的患者[COVID（-）]。结果：1258例患者接受了评估。其中288人（22.9%）被发现患有新冠肺炎。新冠肺炎（+）组最常见和最不常见的诊断分别是非霍奇金淋巴瘤（NHL）（21.7%）和霍奇金淋巴瘤（HL）（6.9%）。新冠肺炎（+）发病率最高和最低的恶性肿瘤分别是多发性骨髓瘤（MM）（35.6%）和慢性粒细胞白血病（CML）患者（17.8%）。新冠（+）慢性淋巴细胞白血病（CLL）患者的中位年龄高于新冠（-）患者（73岁对66岁；p=0.001）。所有死亡均由新冠肺炎（+）患者引起。新冠肺炎（+）组所有患者的死亡率均显著高于新冠肺炎组（22.8%对11.9%；p<0.001）。骨髓增生异常综合征（MDS）（39.5%）和急性白血病（AL）（35.7%）的死亡率在新冠肺炎+组中最高。新冠肺炎（+）CLL（26%对7%）、AL（35.7%对17.7%）和MM（28.6%对9.2%）的死亡率显著高于新冠肺炎组。CML患者中没有因新冠肺炎死亡的病例。79.8%的COVID（+）患者住院治疗，这些患者的死亡率显著高于门诊患者（34.6%对2.8%；p<0.001）。最需要机械通气的患者有MDS（44.8%）和AL（36%）。结论：我们的研究为比较SARS-CoV-2对所有血液系统恶性肿瘤和无COVID-19的恶性患者的影响的文献提供了重要数据

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Klimik Journal MEDICINE, GENERAL & INTERNAL-

CiteScore

0.60

自引率

33.30%

发文量